Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells.

Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S.

Mol Cancer Ther. 2019 Jun;18(6):1181. doi: 10.1158/1535-7163.MCT-19-0471. No abstract available.

2.

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.

Laino AS, Betts BC, Veerapathran A, Dolgalev I, Sarnaik A, Quayle SN, Jones SS, Weber JS, Woods DM.

J Immunother Cancer. 2019 Feb 6;7(1):33. doi: 10.1186/s40425-019-0517-0.

3.

Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.

Maharaj K, Powers JJ, Achille A, Deng S, Fonseca R, Pabon-Saldana M, Quayle SN, Jones SS, Villagra A, Sotomayor EM, Sahakian E, Pinilla-Ibarz J.

Blood Adv. 2018 Nov 13;2(21):3012-3024. doi: 10.1182/bloodadvances.2018020065.

4.

NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.

Liu Y, Li Y, Liu S, Adeegbe DO, Christensen CL, Quinn MM, Dries R, Han S, Buczkowski K, Wang X, Chen T, Gao P, Zhang H, Li F, Hammerman PS, Bradner JE, Quayle SN, Wong KK.

Cancer Res. 2018 Jul 1;78(13):3709-3717. doi: 10.1158/0008-5472.CAN-18-0161. Epub 2018 May 14.

5.

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.

Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S.

Leukemia. 2018 Jan;32(1):49-60. doi: 10.1038/leu.2017.174. Epub 2017 Jun 5.

6.

Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.

Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J.

Breast Cancer Res. 2017 Apr 19;19(1):49. doi: 10.1186/s13058-017-0841-6. No abstract available.

7.

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Adeegbe DO, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, Warner-Hatten T, Castrillon J, Yuan GC, Poudel-Neupane N, Zhang H, Guerriero JL, Han S, Awad MM, Barbie DA, Ritz J, Jones SS, Hammerman PS, Bradner J, Quayle SN, Wong KK.

Cancer Discov. 2017 Aug;7(8):852-867. doi: 10.1158/2159-8290.CD-16-1020. Epub 2017 Apr 13.

8.

Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.

North BJ, Almeciga-Pinto I, Tamang D, Yang M, Jones SS, Quayle SN.

PLoS One. 2017 Mar 6;12(3):e0173507. doi: 10.1371/journal.pone.0173507. eCollection 2017.

9.

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.

Min C, Moore N, Shearstone JR, Quayle SN, Huang P, van Duzer JH, Jarpe MB, Jones SS, Yang M.

PLoS One. 2017 Jan 6;12(1):e0169128. doi: 10.1371/journal.pone.0169128. eCollection 2017.

10.

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.

Huang P, Almeciga-Pinto I, Jarpe M, van Duzer JH, Mazitschek R, Yang M, Jones SS, Quayle SN.

Oncotarget. 2017 Jan 10;8(2):2694-2707. doi: 10.18632/oncotarget.13738.

11.

HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.

Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J.

Breast Cancer Res. 2015 Dec 8;17(1):149. doi: 10.1186/s13058-015-0658-0. Erratum in: Breast Cancer Res. 2017 Apr 19;19(1):49.

12.

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.

Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, O'Donnell E, Selig MK, Quayle SN, Arastu-Kapur S, Kirk C, Boise LH, Jones SS, Raje N.

Br J Haematol. 2015 May;169(3):423-34. doi: 10.1111/bjh.13315. Epub 2015 Feb 23.

PMID:
25709080
13.

HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.

Johnson DP, Spitz GS, Tharkar S, Quayle SN, Shearstone JR, Jones S, McDowell ME, Wellman H, Tyler JK, Cairns BR, Chandrasekharan MB, Bhaskara S.

Oncotarget. 2015 Mar 10;6(7):4863-87.

14.

In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.

Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S.

Mol Cancer Ther. 2014 Dec;13(12):2886-97. doi: 10.1158/1535-7163.MCT-14-0220. Epub 2014 Sep 19. Retraction in: Mol Cancer Ther. 2019 Jun;18(6):1181.

15.

Somatic mutations of PIK3R1 promote gliomagenesis.

Quayle SN, Lee JY, Cheung LW, Ding L, Wiedemeyer R, Dewan RW, Huang-Hobbs E, Zhuang L, Wilson RK, Ligon KL, Mills GB, Cantley LC, Chin L.

PLoS One. 2012;7(11):e49466. doi: 10.1371/journal.pone.0049466. Epub 2012 Nov 14.

16.

Integrative functional genomics identifies RINT1 as a novel GBM oncogene.

Quayle SN, Chheda MG, Shukla SA, Wiedemeyer R, Tamayo P, Dewan RW, Zhuang L, Huang-Hobbs E, Haidar S, Xiao Y, Ligon KL, Hahn WC, Chin L.

Neuro Oncol. 2012 Nov;14(11):1325-31. doi: 10.1093/neuonc/nos246. Epub 2012 Oct 16.

17.

microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.

Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin L.

Cancer Discov. 2012 Aug;2(8):736-49. Epub 2012 Jun 29.

18.

Emerging insights into the molecular and cellular basis of glioblastoma.

Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC.

Genes Dev. 2012 Apr 15;26(8):756-84. doi: 10.1101/gad.187922.112. Review.

19.

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.

Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, Shapiro GI, Hahn WC, Chin L.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11501-6. doi: 10.1073/pnas.1001613107. Epub 2010 Jun 7.

20.

PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.

Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle SN, Ivanova EV, Paik JH, Zhang H, Xiao Y, Perry SR, Hu J, Vinjamoori A, Gan B, Sahin E, Chheda MG, Brennan C, Wang YA, Hahn WC, Chin L, DePinho RA.

Cancer Cell. 2010 May 18;17(5):497-509. doi: 10.1016/j.ccr.2010.03.020.

21.

14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens.

Quayle SN, Sadar MD.

Cancer Lett. 2007 Aug 28;254(1):137-45. Epub 2007 Apr 12.

22.

Novel expressed sequences identified in a model of androgen independent prostate cancer.

Quayle SN, Hare H, Delaney AD, Hirst M, Hwang D, Schein JE, Jones SJ, Marra MA, Sadar MD.

BMC Genomics. 2007 Jan 26;8:32.

23.

Androgen receptor decoy molecules block the growth of prostate cancer.

Quayle SN, Mawji NR, Wang J, Sadar MD.

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1331-6. Epub 2007 Jan 16.

24.

A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells.

Quayle SN, Sadar MD.

Genomics. 2006 May;87(5):633-7. Epub 2006 Jan 24.

25.

Efficient costing and budgeting in the operating theatre.

Quayle SN.

NATNEWS. 1978 Feb;15(2):11-4. No abstract available.

PMID:
307682

Supplemental Content

Loading ...
Support Center